Phase 4
Completed N=2
Effect of Tetrabenazine on Stroop Interference in HD
Huntington Disease
Source: ClinicalTrials.gov NCT01834911 ↗
Enrolled (actual)
2
Serious AEs
0.0%
Results posted
May 2025
Primary outcomePrimary: Change in Stroop Interference Score — -1.97; -1 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Stroop Interference Score |
-1.97; -1 | — |
Eligibility Criteria
Inclusion Criteria
- Established diagnosis of Huntington disease by movement disorders expert
- Patients currently taking tetrabenazine.
- Patients should not have taken dopamine receptor blocking medication for at least three days
Exclusion Criteria
-
Data sourced from ClinicalTrials.gov (NCT01834911). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.